bullish
Wuxi Biologics Placement - Market Is Likely Well-Positioned for the Selldown
333 Views26 Apr 2021 18:52
Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 2.3% of Wuxi Biologics (2269 HK). This is the company's 14th placement since it listed in June 2017.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Zhen Zhou, Toh
APAC IPOs & Placements
Price Chart(Sign Up to Access)
- Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations21 Nov 2021
- Asymchem Labs A/H Listing Early Look - Fast Growing, Relatively Insulated27 Jul 2021
- Wuxi Biologics Placement - Similar Deal Will Yield Similar Results20 Jul 2021
- Wuxi Biologics Placement - Laying the Groundwork for Future Growth02 Feb 2021
- Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?25 Jun 2018
- Autonomous Driving- The Tesla Delusion06 Apr 2018
x